Literature DB >> 11507581

Endocyclophotocoagulation for management of difficult pediatric glaucomas.

D E Neely1, D A Plager.   

Abstract

INTRODUCTION: Experience with endoscopic diode laser cyclophotocoagulation remains limited. We report the efficacy and safety profile of this glaucoma surgery technique in the pediatric population.
METHODS: Retrospective review of 51 endoscopic diode laser cyclophotocoagulation procedures performed on 36 eyes of 29 pediatric patients with glaucoma over a 6-year period. Surgery was performed by using the Microprobe (Endo Optiks, Little Silver, NJ) integrated laser endoscope system. Patients were followed-up for a minimum of 6 months or until declared treatment failures. Treatment success is defined as a postoperative intraocular pressure of < or = 21 mm Hg, with or without adjunctive glaucoma medications.
RESULTS: Baseline mean pretreatment intraocular pressure was 35.06 +/- 8.55 mm Hg. Final postoperative intraocular pressure was 23.63 +/- 11.07 mm Hg (30% decrease) after an average of 1.42 +/- 0.87 endolaser procedures and 19.25 +/- 19.36 months of follow-up. Success rate of the initial procedure at last follow-up was 34%. Nine eyes (25%) were retreated at least once. Cumulative success rate after all procedures at last follow-up was 43%. Mean cumulative arc of treatment was 260 degrees +/- 58 degrees of ciliary processes. Postoperative complications included retinal detachment in 2 patients, hypotony in 1 patient, and progression of vision loss from hand motion to no light perception in 1 patient. All 4 complications occurred in aphakic patients.
CONCLUSIONS: Endoscopic diode laser cyclophotocoagulation is a moderately effective procedure for the management of difficult pediatric glaucomas. Aphakic patients may have an increased risk of significant postoperative complications, such as retinal detachment.

Entities:  

Mesh:

Year:  2001        PMID: 11507581     DOI: 10.1067/mpa.2001.116868

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  21 in total

1.  Endoscopic and transscleral cyclophotocoagulation.

Authors:  P A Bloom; S Dharmaraj
Journal:  Br J Ophthalmol       Date:  2006-06       Impact factor: 4.638

2.  Comparison of acute structural and histopathological changes in human autopsy eyes after endoscopic cyclophotocoagulation and trans-scleral cyclophotocoagulation.

Authors:  Mina B Pantcheva; Malik Y Kahook; Joel S Schuman; Robert J Noecker
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

3.  [Endocyclophotocoagulation for the treatment of glaucoma].

Authors:  M Neuburger; D Böhringer; J F Jordan
Journal:  Ophthalmologe       Date:  2010-01       Impact factor: 1.059

Review 4.  A review of combined phacoemulsification and endoscopic cyclophotocoagulation: efficacy and safety.

Authors:  Wen Sun; Chen-Ying Yu; Jian-Ping Tong
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

Review 5.  [Glaucoma surgery in childhood].

Authors:  T Klink; F Grehn
Journal:  Ophthalmologe       Date:  2011-07       Impact factor: 1.059

Review 6.  Childhood glaucoma surgery in the 21st century.

Authors:  M Papadopoulos; B Edmunds; C Fenerty; P T Khaw
Journal:  Eye (Lond)       Date:  2014-06-13       Impact factor: 3.775

7.  Endocyclophotocoagulation.

Authors:  Suzanne M Falkenberry; Carla J Siegfried
Journal:  Middle East Afr J Ophthalmol       Date:  2009-07

8.  Intermediate results of phaco-endocycloplasty in an exclusive cohort of angle closure glaucoma: potential for change.

Authors:  Vanita Pathak-Ray
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

Review 9.  Endoscopic cyclophotocoagulation.

Authors:  S Lin
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

10.  Vascular effects on ciliary tissue from endoscopic versus trans-scleral cyclophotocoagulation.

Authors:  S C Lin; M J Chen; M S Lin; E Howes; R L Stamper
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.